Cytisinicline + Placebo

Phase 3Recruiting

1 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Vaping Cessation

Conditions

Vaping Cessation

Trial Timeline

May 15, 2026 → Sep 30, 2027

NCT ID

NCT07392125

About Cytisinicline + Placebo

Cytisinicline + Placebo is a phase 3 stage product being developed by Achieve Life Sciences for Vaping Cessation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07392125. Target conditions include Vaping Cessation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07392125	Phase 3	Recruiting	May 15, 2026	Sep 30, 2027	Vaping Cessation
NCT05431387	Phase 2	Completed	Jul 13, 2022	Feb 28, 2023	Vaping
NCT05206370	Phase 3	Completed	Jan 20, 2022	Mar 21, 2023	Smoking Cessation
NCT04576949	Phase 3	Completed	Oct 13, 2020	Dec 23, 2021	Smoking Cessation

Competing Products

1 competing product in Vaping Cessation

See all competitors

Product	Company	Stage	Hype Score
cytisinicline + Placebo	Achieve Life Sciences	Phase 2	25